A carcinogenicity study in mice of a beta-adrenergic antagonist, primidolol; increased total tumour incidence without tissue specificity.

@article{Faccini1981ACS,
  title={A carcinogenicity study in mice of a beta-adrenergic antagonist, primidolol; increased total tumour incidence without tissue specificity.},
  author={J. M. Faccini and E Irisarri and Alastair M. Monro},
  journal={Toxicology},
  year={1981},
  volume={21 4},
  pages={
          279-90
        }
}
The beta-adrenergic blocking agent, primidolol hydrochloride, was administered, mixed in the diet, to mice (CD-1, Charles River, France) for 18 months. Experimental groups comprised untreated controls (100/sex) and those receiving 12.5, 25 and 50 mg drug/kg body weight (50/sex). There were no non-neoplastic lesions which could be attributed to the treatment. The pattern of tumour incidence was sex-related; in females the proportion of tumour-carrying animals was significantly higher in the top… 
24 Citations
Chronic toxicity and carcinogenicity studies with the beta-adrenoceptor antagonist levobunolol.
TLDR
The clinical relevance of the increased incidence of uterine leiomyoma in mice is questionable because it occurred only in one species at more than 200 times the projected therapeutic dose.
Further Studies on the Tumor-Initiating Activity of the Beta-Blocker DL-ZAMI 1305
TLDR
It is demonstrated that the beta-blocker DL-ZAMI 1305 is an initiating carcinogen for the liver of female Wistar rats and inhibits cell proliferation and induces DNA damage in the regenerating rat liver.
The toxicology of the schistosomicidal agent oxamniquine
TLDR
In chronic studies in mice and hamsters with intermittent dosage regimens relevant to likely usage in man, no evidence of carcinogenicity potential was observed at dose levels up to 150 mg/kg; in rats, however, oxamniquine was much more toxic, the female being 8–10 times more sensitive than the male.
Tumor-initiating activity of the beta-blocker ZAMI 1305 in the liver of the female Wistar rat.
TLDR
The data suggest that the oncogenic B-blocker ZAMI 1305 has initiating activity in the liver of the female Wistar rat.
Genotoxicity and carcinogenicity studies of antihypertensive agents.
TLDR
This survey is a compendium of genotoxicity and carcinogenicity information of antihypertensive drugs and indicates the predictivity of genetic toxicology findings for long-term carcinogenesis assays is low.
Studies on the possible mutagenicity of β-adrenergic blocker drugs
The mutagenic potential of nine β-adrenergic blocking agents was investigated in the Ames and micronucleus tests. None of the drugs studied showed any mutagenic response in the Ames test, either in
Update of carcinogenicity studies in animals and humans of 535 marketed pharmaceuticals.
TLDR
The findings of this survey indicate that the evaluation of the benefit/carcinogenic risk ratio should be always made in prescribing a drug.
Recent advances in beta-adrenergic blocking agents.
TLDR
This chapter discusses recent advances in β-adrenergic blocking agents, and the partial agonist activity (P.A.A.) is understood to be the maximum increase in the heart rate observed on the administration of a high dose of the compound to a catecholamine-depleted animal.
Optical isomers of the hepatocarcinogenic beta-blocker ZAMI 1305: influence on nucleic acids synthesis and DNA integrity.
TLDR
The D-isomer and DL-racemic form of the non-oncogenic beta-blocker propranolol inhibit DNA and RNA synthesis and cause DNA fragmentation when added in vitro to isolated liver nuclei, being instead without effect when administered in vivo.
Inhibition of DNA and RNA Synthesis in Rat Liver Nuclei by Oncogenic and Non-oncogenic β-Blockers
TLDR
When administered in vivo both the oncogenic ZAMI 1305 and its non-oncogenic isomer ZAMI 1327 inhibit hepatic DNA and RNA synthesis in female rats, as evaluated by the determination of nucleic acids synthesis in liver nuclei isolated from female rats 5 and 15 min after the injection of the drug.
...
1
2
3
...

References

SHOWING 1-10 OF 16 REFERENCES
Lack of carcinogenicity of oxprenolol, a β-adrenergic blocking agent
Because of an early report that pronethalol, a β -adrenergic blocking agent, produced lymphoreticular tumors in mice, all β -blocking agents as a class came under suspicion. For this reason, several
Preclinical toxicologic evaluation of nadolol, a new β-adrenergic antagonist☆
Abstract Nadolol, 2,3- cis -5-[3-[)1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro-2,3-naphthalenediol, is a potent new β-adrenergic blocking agent that has undergone extensive safety
Influence of biogenic amines on the growth of xenografted human colorectal carcinomas.
The influence of some biogenic amines and amine-receptor-blocking drugs in the growth rate of human colorectal carcinomas propagated as s.c. xenografts in immune-deprived mice was studied. In mice
Tumorigenicity Assays of Sotalol Hydrochloride in Rats and Mice
TLDR
Tumorigenicity studies carried out in rats and mice with sotalol hydrochloride, a beta blocker with little other pharmacologic association with tumor induction, are described.
The effect of propranolol on induction of rat liver tumors by a chemical carcinogen.
TLDR
It is concluded that increased beta adrenergic responsiveness is unlikely to be a process causal to cancer and, moreover, that propranolol somehow facilitates neoplastic transformation in this systern.
The value of the mouse in carcinogenicity testing.
The relative inexpensiveness of obtaining and keeping mice their prolific rate of reproduction and their short life span are advantages in using this species for carcinogenetic tests where large
Carcinogenicity of ‘Alderlin’ (Pronethalol) in Mice*
  • R. Howe
  • Chemistry, Medicine
    Nature
  • 1965
TLDR
'Inderal' (II)' (propranolol) has been shown to be about five times more potent than 'Alderlin' as a (3-adrenergic receptor blocking agent and non-carcinogenic to mice•, rats, guinea-pigs or dog.
Effect of single and twice daily doses of primidolol (UK-11,443) in hypertension.
TLDR
There were significant decreases in baseline values for some of the cardiovascular parameters from Day 1 to Day 7, and in all the parameters in terms of the values 3 hours post-dose on Days 1 and 7, however, the overall change in theiovascular parameters was not significantly different when primidolol and placebo were compared.
Evaluation of the carcinogenicity of chemicals: a review of the Monograph Program of the International Agency for Research on Cancer (1971 to 1977).
TLDR
The criteria on which the carcinogenicity of chemicals to humans and/or experimental animals was assessed, from the initiation of this program in 1971 until 1977, have recently been revised and are briefly discussed.
Carcinogenesis and sanity.
  • F. Roe
  • Chemistry, Medicine
    Food and cosmetics toxicology
  • 1968
TLDR
The evaluation of food from the viewpoint of possible carcinogenic hazard should include a search for ways of reducing the existing human cancer burden, and the system of scrutiny of food constituents for safety should be more flexible, so that priority can be given to potentially more serious hazards, whether they be additives or contaminants.
...
1
2
...